<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1025-028X</journal-id>
<journal-title><![CDATA[Vaccimonitor]]></journal-title>
<abbrev-journal-title><![CDATA[Vaccimonitor]]></abbrev-journal-title>
<issn>1025-028X</issn>
<publisher>
<publisher-name><![CDATA[Finlay Ediciones]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1025-028X2001000400002</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Validación de un ELISA para la cuantificación de IgG antipolisacárido capsular de Neisseria meningitidis serogrupo C en sueros de ratones]]></article-title>
<article-title xml:lang="en"><![CDATA[Validation of the ELISA for quantifying capsular anti-polysaccharide IgG of Neisseria meningitidis of the serogroup C in mice sera]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cuello]]></surname>
<given-names><![CDATA[Maribel]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Acosta]]></surname>
<given-names><![CDATA[Yanely]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[Juan C]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cabrera]]></surname>
<given-names><![CDATA[Osmir]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ochoa]]></surname>
<given-names><![CDATA[Rolando]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Balboa]]></surname>
<given-names><![CDATA[Julio A]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Soto]]></surname>
<given-names><![CDATA[Carmen R]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[Miguel E]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sierra]]></surname>
<given-names><![CDATA[Gustavo]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,Instituto Finlay  ]]></institution>
<addr-line><![CDATA[Ciudad de La Habana ]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2001</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2001</year>
</pub-date>
<volume>10</volume>
<numero>4</numero>
<fpage>7</fpage>
<lpage>13</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S1025-028X2001000400002&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S1025-028X2001000400002&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S1025-028X2001000400002&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Se desarrolló un ensayo inmunoenzimático de fase sólida (ELISA) indirecto para cuantificar anticuerpos IgG específicos antipolisacárido C en ratón, utilizando un prerrecubrimiento con Poli-L-lisina y luego el polisacárido capsular de Neisseria meningitidis serogrupo C (Instituto Finlay, La Habana, Cuba), para evaluar la respuesta inmune contra este componente en candidatos vacunales en estudios preclínicos. Como conjugado se utilizó anti-IgG ratón conjugado a fosfatasa alcalina, el cual se une a los anticuerpos antipolisacárido C producidos en ratones. La reacción es evidenciada por la degradación del sustrato p-nitrofenilfosfato. La detectibilidad del ensayo fue de 123,74 U/mL y la especificidad fue alta. La precisión interensayo, intraensayo y total, así como las desviaciones de la recuperación, linealidad y paralelismo no sobrepasaron el 10%. El ELISA permitió cuantificar los anticuerpos antipolisacárido C inducidos en ratones tanto por candidatos vacunales conjugados, como por la vacuna VA-MENGOC-BC y el polisacárido C sin conjugar.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[An indirect enzyme-linked immunoabsorbent assay (ELISA) was developed to determine antibody anti-polysaccharide C mouse IgG. Polystyrene plates precoating with poly-L-lysine, then Neisseria meningitidis group C polysaccharide (Finlay Institute, Havana, Cuba) was used to evaluated the immune response against this component in a candidate vaccine in pre-clinical studies. Alkaline phosphatase conjugate was used for recognizing mouse antibodies against polysaccharide C. The enzymatic reaction is evidenced by using the specific substrate p-nitrophenylphosphate. The detection limit of the assay was 123,74 U/mL, the specificity of assay was high. Intra-and interassay lack of precision, parallelism, linearity, and recovery were ± 10% of the expected values.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[ELISA]]></kwd>
<kwd lng="es"><![CDATA[antipolisacárido C]]></kwd>
<kwd lng="es"><![CDATA[Neisseria meningitidis serogrupo C]]></kwd>
<kwd lng="es"><![CDATA[validación]]></kwd>
<kwd lng="en"><![CDATA[ELISA]]></kwd>
<kwd lng="en"><![CDATA[Antipolysaccharide C]]></kwd>
<kwd lng="en"><![CDATA[Neisseria meningitidis serogroup C]]></kwd>
<kwd lng="en"><![CDATA[validation]]></kwd>
</kwd-group>
</article-meta>
</front><body><![CDATA[ <p align="right"><font face="Verdana" size="2"><b>ARTICULOS ORIGINALES</b></font></p>     <p align="right">&nbsp;</p>     <p align="right"><font face="Verdana, Arial, Helvetica, sans-serif"><strong><font size="4">Validaci&oacute;n de un ELISA para la cuantificaci&oacute;n de IgG antipolisac&aacute;rido    capsular de Neisseria meningitidis serogrupo  C en sueros de ratones.</font></strong></font></p>     <p align="left">&nbsp;</p>     <p align="right"><font size="3" face="Verdana, Arial, Helvetica, sans-serif"><strong>Validation of the ELISA for quantifying capsular anti-polysaccharide IgG of Neisseria meningitidis of the serogroup C in mice sera.    <br> </strong></font></p>     <p align="left">&nbsp;</p>     <p align="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><strong>Maribel Cuello, Yanely Acosta , Juan C. Mart&iacute;nez, Osmir Cabrera, Rolando Ochoa, Julio A Balboa, Carmen R. Soto,       Miguel E. Mart&iacute;nez, y Gustavo Sierra.    <br> </strong></font></p>     <p align="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">Instituto Finlay. Centro de Investigaci&oacute;n-Producci&oacute;n de Vacunas y Sueros. Ciudad de La Habana, Cuba.    ]]></body>
<body><![CDATA[<br> E-mail:<a href="mailto:ocabrera@finlay.edu.cu">mcuello@finlay.edu.cu</a></font></p> <hr>     <p align="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><strong>RESUMEN    <br>   </strong></font></p>     <p align="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">Se desarroll&oacute; un ensayo inmunoenzim&aacute;tico de fase s&oacute;lida (ELISA) indirecto para cuantificar anticuerpos IgG    <br>   espec&iacute;ficos antipolisac&aacute;rido C en rat&oacute;n, utilizando un prerrecubrimiento con Poli-L-lisina y luego el polisac&aacute;rido    <br>   capsular de Neisseria meningitidis serogrupo C (Instituto Finlay, La Habana, Cuba), para evaluar la respuesta    <br>   inmune contra este componente en candidatos vacunales en estudios precl&iacute;nicos. Como conjugado se utiliz&oacute;    <br>   anti-IgG rat&oacute;n conjugado a fosfatasa alcalina, el cual se une a los anticuerpos antipolisac&aacute;rido C producidos en    <br>   ratones. La reacci&oacute;n es evidenciada por la degradaci&oacute;n del sustrato p-nitrofenilfosfato. La detectibilidad del    <br>   ensayo fue de 123,74 U/mL y la especificidad fue alta. La precisi&oacute;n interensayo, intraensayo y total, as&iacute; como las    desviaciones de la recuperaci&oacute;n, linealidad y paralelismo no sobrepasaron el 10%. El ELISA permiti&oacute; cuantificar    los anticuerpos antipolisac&aacute;rido C inducidos en ratones tanto por candidatos vacunales conjugados, como por la    vacuna VA-MENGOC-BC y el polisac&aacute;rido C sin conjugar.<strong>    ]]></body>
<body><![CDATA[<br> </strong></font></p>     <p align="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><strong>Palabras claves: </strong>ELISA, antipolisac&aacute;rido C, Neisseria meningitidis serogrupo C, validaci&oacute;n.</font></p> <hr>     <p align="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><strong>  ABSTRACT</strong></font></p>     <p align="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif"> An indirect enzyme-linked immunoabsorbent assay (ELISA) was developed to determine antibody anti-polysaccharide C    mouse IgG. Polystyrene plates precoating with poly-L-lysine, then Neisseria meningitidis group C polysaccharide (Finlay    Institute, Havana, Cuba) was used to evaluated the immune response against this component in a candidate vaccine in    pre-clinical studies. Alkaline phosphatase conjugate was used for recognizing mouse antibodies against polysaccharide C.   The enzymatic reaction is evidenced by using the specific substrate p-nitrophenylphosphate. The detection limit of the    assay was 123,74 U/mL, the specificity of assay was high. Intra-and interassay lack of precision, parallelism, linearity, and    recovery were &plusmn; 10% of the expected values.<strong>    <br>   </strong></font></p>     <p align="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><strong>Keywords: </strong>Antipolysaccharide C ELISA, Neisseria meningitidis serogroup C, validation.</font></p> <hr>     <p align="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><strong>texto completo en pdf</strong></font></p>     <p align="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><B>REFERENCIAS</B> </font></p>     <!-- ref --><P ALIGN="JUSTIFY"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Poolman JT. Development of a meningococcal vaccine. Infect Agents Dis 1991; 4:13-28. </font>     <!-- ref --><P ALIGN="JUSTIFY"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Peeters CCA, Tenbergen-Meekes AM., Poolman Beurret JT, Zegers M BJM and Rijkers GT Effect of carrier priming on immunogenicity of Saccharide_Protein conjugate vaccine. Infect and Immun 1991; 59 (10):3504-3510. </font>     <!-- ref --><P ALIGN="JUSTIFY"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">3. POOLMAN JT. Polysaccharides and Membrane Vaccines. In A. Mizrahi (ed.), Bacterial vaccines. New York: Wiley-Liss, 1990; 57-86. </font>     <!-- ref --><P ALIGN="JUSTIFY"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Lieberman JM, Chiu SS, Wong VK, Partridge S, Chang SJ, Chiu CY. Safety and inmunogenicity of a serogroups A/C. Neisseria meningitides oligosaccharide- protein conjugate vaccine in young children. JAMA 1996; 275:1492-1503. </font>     <!-- ref --><P ALIGN="JUSTIFY"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Guide for the care and use of laboratory animal. EEC council Directive 86 / 609, OJL 358, 1, Dec. 12, 1987.  </font>     <P ALIGN="JUSTIFY"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Nerey, M. Normalizaci&oacute;n de un ELISA cuantitativo para IgG anti-polisac&aacute;rido del meningococo serogrupo C. Estudio de la respuesta immune humoral en vacunados con VA-MENGOC-BC&#174;. Tesis de Grado. Ciudad de La Habana, Cuba: Universidad de La Habana; 1992. </font>     <!-- ref --><P ALIGN="JUSTIFY"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Plikaytis BD, Turner SH, Gheesling LL, Carlone GM. Comparinsons of standard curve-fitting methods to quantitate Neisseria meningitidis group A polysaccharide antibody levels by Enzyme-Linked Immunosorbent Assay. J Clin Microb 1991; 29(7): 1439-1446. </font>     <!-- ref --><P ALIGN="JUSTIFY"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Broughton PMG, Bergonzi C, Lindstedt G, Loeber JG, Malan PG. Guidelines for the evaluation of diagnostic kits. Part 2. General principles and outline procedures for the evaluation of kits for qualitative tests. European Committee for Clinical Laboratory Standards. 1986; 3(3). </font>     <!-- ref --><P ALIGN="JUSTIFY"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Kuhlmann WD, Rieger J. Diphtheria immunity of a west German population by measurement of antitoxin antibodies with enzyme-linked immunosorbent assay. Immunol Infect Dis 1995; 5:10-14. </font>     <!-- ref --><P ALIGN="JUSTIFY"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Camargo ME, Silveira L, Furuta JA, Oliveira EPT, Germek OA. Immunoenzymatic assay of antidiphtheric toxin antibodies in human serum. J Clin Microb 1984; 20(4):772-4. </font>     <!-- ref --><P ALIGN="JUSTIFY"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Ochoa R.A, Mart&iacute;nez J.C, Estrada E, et al. Principios y procedimientos para la validaci&oacute;n de inmunoensayos cuantitativos empleados para evaluar la inmunogenicidad de vacunas. VacciMonitor 1999; 8(10):9-13. </font>     <!-- ref --><P ALIGN="JUSTIFY"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Ochoa R, Mart&iacute;nez JC, Fernol X, et. al. Gu&iacute;a para la estandarizaci&oacute;n de t&eacute;cnicas inmunoenzim&aacute;ticas en ensayos de vacunas. VacciMonitor 2000; 9(3): 13-18. </font>     <!-- ref --><P ALIGN="JUSTIFY"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Plikaytis BD, Holder PF, Pais LB, Maslanka SE; Gheesling LL, Carlone GM. Determination of parellelism and nonparallelism is bioassay dilution curves. J Clin. Microbiol 1994; 32:2441-2447. </font>     <!-- ref --><P ALIGN="JUSTIFY"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Gu&iacute;a de la OMS sobre los Requisitos de las Pr&aacute;cticas adecuadas de Fabricaci&oacute;n (PAF). 1998. </font>     <!-- ref --><P ALIGN="JUSTIFY"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Nerey M, Ochoa R, Mart&iacute;nez JC, et. al. Validaci&oacute;n de un ELISA para la cuantificaci&oacute;n de IgG humana antipolisac&aacute;rido capsular de Neisseria meningitidis serogrupo C. Biotecnolog&iacute;a Aplicada 1999; 16:113-115. </font>     <!-- ref --><p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Andersen J, Berthelsen L, Lind I. Measurement of antibodies against meningococcal capsular polysaccharides B and C in enzyme-linked immunosorbent assays: towards an improved surveillance of meningococcal disease. Clin Diagn Lab Immunol 1997; 4:345-51.</font><!-- ref --><P ALIGN="JUSTIFY"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">17. Aggerbeck H, Norgaard-Pedersen B, Heron I. Simultaneous quantitation of diphtheria and tetanus antibodies by double antigen, time-resolved fluorescence immunoassay. J Immunol Methods 1996; 171-183. </font>     <!-- ref --><P ALIGN="JUSTIFY"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Chaloner-Larsson G, Anderson R, Egan A. A WHO guide to good manufacturing practice (GMP) requirements. Part 2: Validation. Validation of analytical assays. WHO Geneva. 1997; 65-95. </font>     <!-- ref --><P ALIGN="JUSTIFY"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">19. Cruces A. Estandarizaci&oacute;n de un ELISA para la cuantificaci&oacute;n de antitoxina dift&eacute;rica en sueros humanos. Tesis de Grado. Ciudad de La Habana, Cuba: Universidad de La Habana. 1998. </font>      ]]></body><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Poolman]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Development of a meningococcal vaccine]]></article-title>
<source><![CDATA[Infect Agents Dis]]></source>
<year>1991</year>
<volume>4</volume>
<page-range>13-28</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Peeters]]></surname>
<given-names><![CDATA[CCA]]></given-names>
</name>
<name>
<surname><![CDATA[Tenbergen-Meekes]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Poolman Beurret]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
<name>
<surname><![CDATA[Zegers]]></surname>
<given-names><![CDATA[MBJM]]></given-names>
</name>
<name>
<surname><![CDATA[Rijkers]]></surname>
<given-names><![CDATA[GT]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Effect of carrier priming on immunogenicity of Saccharide_Protein conjugate vaccine]]></article-title>
<source><![CDATA[Infect and Immun]]></source>
<year>1991</year>
<volume>59</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>3504-3510</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[POOLMAN  ]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Polysaccharides and Membrane Vaccines]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Mizrahi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Bacterial vaccines]]></source>
<year>1990</year>
<page-range>57-86</page-range><publisher-loc><![CDATA[New York ]]></publisher-loc>
<publisher-name><![CDATA[Wiley-Liss]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lieberman]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Chiu]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
<name>
<surname><![CDATA[Wong]]></surname>
<given-names><![CDATA[VK]]></given-names>
</name>
<name>
<surname><![CDATA[Partridge]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Chiu]]></surname>
<given-names><![CDATA[CY]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Safety and inmunogenicity of a serogroups A/C: Neisseria meningitides oligosaccharide- protein conjugate vaccine in young children]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>1996</year>
<volume>275</volume>
<page-range>1492-1503</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="">
<collab>Guide for the care and use of laboratory animal^dEEC council Directive 86 / 609, OJL 358, 1,</collab>
<source><![CDATA[]]></source>
<year>Dec.</year>
<month> 1</month>
<day>2,</day>
</nlm-citation>
</ref>
<ref id="B6">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Plikaytis]]></surname>
<given-names><![CDATA[BD]]></given-names>
</name>
<name>
<surname><![CDATA[Turner]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
<name>
<surname><![CDATA[Gheesling]]></surname>
<given-names><![CDATA[LL]]></given-names>
</name>
<name>
<surname><![CDATA[Carlone]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Comparinsons of standard curve-fitting methods to quantitate Neisseria meningitidis group A polysaccharide antibody levels by Enzyme-Linked Immunosorbent Assay]]></article-title>
<source><![CDATA[J Clin Microb]]></source>
<year>1991</year>
<volume>29</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1439-1446</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Broughton  ]]></surname>
<given-names><![CDATA[PMG]]></given-names>
</name>
<name>
<surname><![CDATA[Bergonzi  ]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Lindstedt  ]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Loeber  ]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Malan  ]]></surname>
<given-names><![CDATA[PG]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Guidelines for the evaluation of diagnostic kits: General principles and outline procedures for the evaluation of kits for qualitative tests]]></article-title>
<source><![CDATA[European Committee for Clinical Laboratory Standards]]></source>
<year>1986</year>
<volume>3</volume>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
<ref id="B8">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kuhlmann]]></surname>
<given-names><![CDATA[WD]]></given-names>
</name>
<name>
<surname><![CDATA[Rieger]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Diphtheria immunity of a west German population by measurement of antitoxin antibodies with enzyme-linked immunosorbent assay]]></article-title>
<source><![CDATA[Immunol Infect Dis]]></source>
<year>1995</year>
<volume>5</volume>
<page-range>10-14</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Camargo]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Silveira]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Furuta]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Oliveira]]></surname>
<given-names><![CDATA[EPT]]></given-names>
</name>
<name>
<surname><![CDATA[Germek]]></surname>
<given-names><![CDATA[OA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Immunoenzymatic assay of antidiphtheric toxin antibodies in human serum]]></article-title>
<source><![CDATA[J Clin Microb]]></source>
<year>1984</year>
<volume>20</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>772-4</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ochoa]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Estrada]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang="es"><![CDATA[Principios y procedimientos para la validación de inmunoensayos cuantitativos empleados para evaluar la inmunogenicidad de vacunas]]></article-title>
<source><![CDATA[VacciMonitor]]></source>
<year>1999</year>
<volume>8</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>9-13</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ochoa]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Fernol]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang="es"><![CDATA[Guía para la estandarización de técnicas inmunoenzimáticas en ensayos de vacunas]]></article-title>
<source><![CDATA[VacciMonitor]]></source>
<year>2000</year>
<volume>9</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>13-18</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Plikaytis]]></surname>
<given-names><![CDATA[BD]]></given-names>
</name>
<name>
<surname><![CDATA[Holder]]></surname>
<given-names><![CDATA[PF]]></given-names>
</name>
<name>
<surname><![CDATA[Pais]]></surname>
<given-names><![CDATA[LB]]></given-names>
</name>
<name>
<surname><![CDATA[Maslanka]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Gheesling]]></surname>
<given-names><![CDATA[LL]]></given-names>
</name>
<name>
<surname><![CDATA[Carlone]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Determination of parellelism and nonparallelism is bioassay dilution curves]]></article-title>
<source><![CDATA[J Clin Microbiol]]></source>
<year>1994</year>
<volume>32</volume>
<page-range>2441-2447</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>14</label><nlm-citation citation-type="">
<source><![CDATA[Guía de la OMS sobre los Requisitos de las Prácticas adecuadas de Fabricación (PAF)]]></source>
<year>1998</year>
</nlm-citation>
</ref>
<ref id="B14">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nerey]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ochoa]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<article-title xml:lang="es"><![CDATA[Validación de un ELISA para la cuantificación de IgG humana antipolisacárido capsular de Neisseria meningitidis serogrupo C]]></article-title>
<source><![CDATA[Biotecnología Aplicada]]></source>
<year>1999</year>
<volume>16</volume>
<page-range>113-115</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Andersen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Berthelsen]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Lind]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Measurement of antibodies against meningococcal capsular polysaccharides B and C in enzyme-linked immunosorbent assays towards an improved surveillance of meningococcal disease]]></article-title>
<source><![CDATA[Clin Diagn Lab Immunol]]></source>
<year>1997</year>
<volume>4</volume>
<page-range>345-51</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aggerbeck]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Norgaard Pedersen]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Heron]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Simultaneous quantitation of diphtheria and tetanus antibodies by double antigen time resolved fluorescence immunoassay]]></article-title>
<source><![CDATA[J Immunol Methods]]></source>
<year>1996</year>
<page-range>171-183</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>18</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chaloner-Larsson]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Egan]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[A WHO guide to good manufacturing practice (GMP) requirements: Validation. Validation of analytical assays]]></source>
<year>1997</year>
<page-range>65-95</page-range><publisher-loc><![CDATA[Geneva ]]></publisher-loc>
<publisher-name><![CDATA[WHO]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B18">
<label>19</label><nlm-citation citation-type="confpro">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cruces]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Estandarización de un ELISA para la cuantificación de antitoxina diftérica en sueros humanos]]></source>
<year>1998</year>
<conf-name><![CDATA[ Tesis de Grado]]></conf-name>
<conf-loc>Ciudad de La Habana </conf-loc>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
